-$0.57 Earnings Per Share Expected for Omega Therapeutics Inc (NASDAQ:OMGA) This Quarter

Analysts predict that Omega Therapeutics Inc (NASDAQ:OMGA) will announce earnings per share (EPS) of ($0.57) for the current quarter, according to Zacks. Zero analysts have made estimates for Omega Therapeutics’ earnings. The lowest EPS estimate is ($0.74) and the highest is ($0.46). The company is scheduled to report its next quarterly earnings results on Wednesday, February 9th.

According to Zacks, analysts expect that Omega Therapeutics will report full-year earnings of ($2.91) per share for the current fiscal year, with EPS estimates ranging from ($3.87) to ($1.77). For the next fiscal year, analysts expect that the company will report earnings of ($3.34) per share, with EPS estimates ranging from ($3.73) to ($2.56). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Omega Therapeutics.

Omega Therapeutics (NASDAQ:OMGA) last released its earnings results on Wednesday, November 10th. The company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.09).

OMGA has been the subject of a number of analyst reports. Jefferies Financial Group initiated coverage on shares of Omega Therapeutics in a research note on Tuesday, August 24th. They set a “buy” rating and a $30.00 price target for the company. Wedbush started coverage on shares of Omega Therapeutics in a research note on Tuesday, August 24th. They set an “outperform” rating and a $36.00 price target for the company. The Goldman Sachs Group started coverage on shares of Omega Therapeutics in a report on Tuesday, August 24th. They set a “neutral” rating and a $22.00 price objective for the company. Zacks Investment Research lowered shares of Omega Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 13th. Finally, Piper Sandler began coverage on shares of Omega Therapeutics in a report on Tuesday, August 24th. They set an “overweight” rating and a $30.00 price objective for the company. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $28.20.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. bought a new position in shares of Omega Therapeutics during the third quarter worth $4,168,000. BlackRock Inc. bought a new stake in Omega Therapeutics in the 3rd quarter valued at $18,061,000. CHI Advisors LLC acquired a new stake in Omega Therapeutics in the 3rd quarter valued at $19,904,000. 72 Investment Holdings LLC acquired a new stake in Omega Therapeutics in the 3rd quarter valued at $6,653,000. Finally, Sphera Funds Management LTD. acquired a new stake in Omega Therapeutics in the 3rd quarter valued at $9,952,000. 54.25% of the stock is currently owned by institutional investors.

Shares of NASDAQ OMGA traded down $0.32 during mid-day trading on Thursday, hitting $17.00. The company had a trading volume of 97,474 shares, compared to its average volume of 101,414. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.62 and a current ratio of 16.69. The firm’s 50-day moving average price is $21.19. Omega Therapeutics has a 12 month low of $15.50 and a 12 month high of $31.41.

Omega Therapeutics Company Profile

Omega Therapeutics Inc is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc is based in CAMBRIDGE, Mass.

Read More: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on Omega Therapeutics (OMGA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omega Therapeutics (NASDAQ:OMGA)

Receive News & Ratings for Omega Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.